

7. Colon and Rectum – Biomarkers ColonRectum 3.4.0.0 – CAP Protocol. <http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-colon-16protocol-3400.pdf> Accessed on 15-September-2016.
8. Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 [Published online October 5, 2015]. *J Clin Oncol*. doi: 10.1200/JCO.2015.63.9674.
9. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med*. 2004 Jul 22;351(4):337-45.
10. Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and their downstream targets. *Biochim Biophys Acta*. 2007 Aug;1773(8):1177-95.
11. Chan, E. KRAS in Colorectal Cancer. 2015. My Cancer Genome <https://www.mycancergenome.org/content/disease/colorectal-cancer/kras/> Accessed on 15-Sep-2016.
12. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol*. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116.
13. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. *Ann Oncol*. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378.
14. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. *Cancer Treat Rev*. 2015 Sep;41(8):653-9. doi: 10.1016/j.ctrv.2015.05.008.
15. Wong NA, Gonzalez D, Salto-Tellez M, Butler R, Diaz-Cano SJ, Ilyas M, Newman W, Shaw E, Taniere P, Walsh SV; Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. *J Clin Pathol*. 2014 Sep;67(9):751-7.
16. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014;25(Suppl. 3):iii1–9.